Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 311

1.

Precision oncology giveth and precision oncology taketh away.

Saltz LB.

Lancet Oncol. 2019 Mar 8. pii: S1470-2045(19)30095-6. doi: 10.1016/S1470-2045(19)30095-6. [Epub ahead of print] No abstract available.

PMID:
30857958
2.

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.

Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S.

Eur J Cancer. 2019 Feb 28;111:82-93. doi: 10.1016/j.ejca.2019.01.022. [Epub ahead of print]

PMID:
30826660
3.

Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).

Morales-Oyarvide V, Yuan C, Babic A, Zhang S, Niedzwiecki D, Brand-Miller JC, Sampson-Kent L, Ye X, Li Y, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Wolpin BM, Meyerhardt JA, Fuchs CS, Ng K.

J Natl Cancer Inst. 2019 Feb 1;111(2):170-179. doi: 10.1093/jnci/djy098.

PMID:
30726946
4.

Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).

Schrag D, Weiser M, Saltz L, Mamon H, Gollub M, Basch E, Venook A, Shi Q.

Clin Trials. 2019 Jan 28:1740774518824539. doi: 10.1177/1740774518824539. [Epub ahead of print]

PMID:
30688523
5.

Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability.

Raj N, Shah R, Stadler Z, Mukherjee S, Chou J, Untch B, Li J, Kelly V, Saltz LB, Mandelker D, Ladanyi M, Berger MF, Klimstra DS, Reidy-Lagunes D, Osoba M.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00267. Epub 2018 Apr 19.

6.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
7.

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.

Cocco E, Benhamida J, Middha S, Zehir A, Mullaney K, Shia J, Yaeger R, Zhang L, Wong D, Villafania L, Nafa K, Scaltriti M, Drilon A, Saltz L, Schram AM, Stadler ZK, Hyman DM, Benayed R, Ladanyi M, Hechtman JF.

Cancer Res. 2019 Mar 15;79(6):1047-1053. doi: 10.1158/0008-5472.CAN-18-3126. Epub 2019 Jan 14.

PMID:
30643016
8.

Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy.

Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, Widmar M, Ganesh K, Yaeger R, Cercek A, Weiser MR, Nash GM, Guillem JG, Temple LKF, Chalasani SB, Fuqua JL, Petkovska I, Wu AJ, Reyngold M, Vakiani E, Shia J, Segal NH, Smith JD, Crane C, Gollub MJ, Gonen M, Saltz LB, Garcia-Aguilar J, Paty PB.

JAMA Oncol. 2019 Jan 10:e185896. doi: 10.1001/jamaoncol.2018.5896. [Epub ahead of print]

PMID:
30629084
9.

SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.

Wasserman I, Lee LH, Ogino S, Marco MR, Wu C, Chen X, Datta J, Sadot E, Szeglin B, Guillem JG, Paty PB, Weiser MR, Nash GM, Saltz L, Barlas A, Manova-Todorova K, Uppada SPB, Elghouayel AE, Ntiamoah P, Glickman JN, Hamada T, Kosumi K, Inamura K, Chan AT, Nishihara R, Cercek A, Ganesh K, Kemeny NE, Dhawan P, Yaeger R, Sawyers CL, Garcia-Aguilar J, Giannakis M, Shia J, Smith JJ.

Clin Cancer Res. 2019 Mar 15;25(6):1948-1956. doi: 10.1158/1078-0432.CCR-18-1726. Epub 2018 Dec 26.

PMID:
30587545
10.

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.

Loupakis F, Hurwitz HI, Saltz L, Arnold D, Grothey A, Nguyen QL, Osborne S, Talbot J, Srock S, Lenz HJ.

Br J Cancer. 2018 Dec;119(12):1451-1455. doi: 10.1038/s41416-018-0304-6. Epub 2018 Nov 29.

PMID:
30487637
11.

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.

Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian Y, O'Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK.

J Clin Oncol. 2019 Feb 1;37(4):286-295. doi: 10.1200/JCO.18.00283. Epub 2018 Oct 30.

PMID:
30376427
12.

FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.

Mondaca S, Chatila WK, Bates D, Hechtman JF, Cercek A, Segal NH, Stadler ZK, Varghese AM, Kundra R, Capanu M, Shia J, Schultz N, Saltz L, Yaeger R.

Clin Colorectal Cancer. 2018 Sep 21. pii: S1533-0028(18)30390-6. doi: 10.1016/j.clcc.2018.09.005. [Epub ahead of print]

13.

Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?

Gollub MJ, Blazic I, Bates DDB, Campbell N, Knezevic A, Gonen M, Lynn P, Weiser MR, Garcia-Aguilar J, Hötker AM, Cercek A, Saltz L.

Eur Radiol. 2019 Apr;29(4):1733-1742. doi: 10.1007/s00330-018-5726-2. Epub 2018 Oct 2.

PMID:
30280248
14.

Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment.

Burris HA, Saltz LB, Yu PP.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):139-146. doi: 10.1200/EDBK_200825. Review.

PMID:
30231307
15.

Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.

Liu S, Gӧnen M, Stadler ZK, Weiser MR, Hechtman JF, Vakiani E, Wang T, Vyas M, Joneja U, Al-Bayati M, Segal NH, Smith JJ, King S, Guercio S, Ntiamoah P, Markowitz AJ, Zhang L, Cercek A, Garcia-Aguilar J, Saltz LB, Diaz LA, Klimstra DS, Shia J.

Mod Pathol. 2019 Jan;32(1):110-121. doi: 10.1038/s41379-018-0114-7. Epub 2018 Aug 30.

16.

Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance).

Van Blarigan EL, Ou FS, Niedzwiecki D, Zhang S, Fuchs CS, Saltz L, Mayer RJ, Venook A, Ogino S, Song M, Benson A, Hantel A, Atkins JN, Giovannucci EL, Meyerhardt JA.

Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1227-1230. doi: 10.1158/1055-9965.EPI-18-0487. Epub 2018 Jul 23.

PMID:
30038051
17.

Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).

Guercio BJ, Zhang S, Niedzwiecki D, Li Y, Babic A, Morales-Oyarvide V, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Zoltick ES, Stampfer M, Ng K, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS.

PLoS One. 2018 Jul 19;13(7):e0199244. doi: 10.1371/journal.pone.0199244. eCollection 2018.

18.

Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):874-901. doi: 10.6004/jnccn.2018.0061.

PMID:
30006429
19.

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):852-871. doi: 10.6004/jnccn.2018.0060.

PMID:
30006428
20.

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2018 Jun;16(6):693-702. doi: 10.6004/jnccn.2018.0056.

PMID:
29891520
21.

Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA.

JNCI Cancer Spectr. 2018 Feb;2(2):pky017. doi: 10.1093/jncics/pky017. Epub 2018 May 30.

22.

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK.

Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.

PMID:
29848569
23.

Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Ng K, Meyerhardt JA.

JAMA Oncol. 2018 Jun 1;4(6):783-790. doi: 10.1001/jamaoncol.2018.0126.

PMID:
29710284
24.

NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021.

PMID:
29632055
25.

Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.

Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, Guillem JG, Paty PB, Yaeger R, Stadler ZK, Seier K, Gonen M, Segal NH, Reidy DL, Varghese A, Shia J, Vakiani E, Wu AJ, Crane CH, Gollub MJ, Garcia-Aguilar J, Saltz LB, Weiser MR.

JAMA Oncol. 2018 Jun 14;4(6):e180071. doi: 10.1001/jamaoncol.2018.0071. Epub 2018 Jun 14.

PMID:
29566109
26.

Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs.

Green AK, Saltz LB.

J Clin Oncol. 2018 May 1;36(13):1381-1382. doi: 10.1200/JCO.2018.78.4397. Epub 2018 Mar 16. No abstract available.

PMID:
29547344
27.

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS.

J Clin Oncol. 2018 Apr 10;36(11):1112-1120. doi: 10.1200/JCO.2017.75.5413. Epub 2018 Feb 28.

PMID:
29489429
28.

First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors.

Keedy VL, Lenz HJ, Saltz L, Whisenant JG, Berlin JD, Camacho LH.

Invest New Drugs. 2018 Oct;36(5):860-868. doi: 10.1007/s10637-018-0567-z. Epub 2018 Jan 29.

PMID:
29376210
29.

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA Jr, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM.

Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. doi: 10.1158/1078-0432.CCR-17-3099. Epub 2018 Jan 24.

30.

Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance).

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Ye X, Zhang S, Song M, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Meyerhardt JA.

Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):438-445. doi: 10.1158/1055-9965.EPI-17-0689. Epub 2018 Jan 22.

PMID:
29358223
31.

The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.

Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S.

J Natl Cancer Inst. 2018 Aug 1;110(8):888-894. doi: 10.1093/jnci/djx288.

PMID:
29346573
32.

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.

Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, Jayakumaran G, Middha S, Zehir A, Donoghue MTA, You D, Viale A, Kemeny N, Segal NH, Stadler ZK, Varghese AM, Kundra R, Gao J, Syed A, Hyman DM, Vakiani E, Rosen N, Taylor BS, Ladanyi M, Berger MF, Solit DB, Shia J, Saltz L, Schultz N.

Cancer Cell. 2018 Jan 8;33(1):125-136.e3. doi: 10.1016/j.ccell.2017.12.004.

33.

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.

Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

PMID:
29295881
34.

Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome.

Konishi T, Shimada Y, Hsu M, Tufts L, Jimenez-Rodriguez R, Cercek A, Yaeger R, Saltz L, Smith JJ, Nash GM, Guillem JG, Paty PB, Garcia-Aguilar J, Gonen M, Weiser MR.

JAMA Oncol. 2018 Mar 1;4(3):309-315. doi: 10.1001/jamaoncol.2017.4420.

35.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD).

J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.

36.

Outcomes of ICU Admission of Patients With Progressive Metastatic Gastrointestinal Cancer.

Epstein AS, Yang A, Colbert LE, Voigt LP, Meadows J, Goldberg JI, Saltz LB.

J Intensive Care Med. 2017 Jan 1:885066617748874. doi: 10.1177/0885066617748874. [Epub ahead of print]

37.

The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer.

Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Saltz LB, Balachandran VP, Peter Kingham T, DeMatteo RP, Allen PJ, Jarnagin WR, D'Angelica MI.

Ann Surg Oncol. 2018 Feb;25(2):431-438. doi: 10.1245/s10434-017-6264-x. Epub 2017 Nov 27.

PMID:
29181680
38.

Author's Response.

Desai AV, Epstein AS, Colbert LE, Saltz LB.

J Pain Symptom Manage. 2018 Jan;55(1):e2-e3. doi: 10.1016/j.jpainsymman.2017.11.003. Epub 2017 Nov 13. No abstract available.

PMID:
29146195
39.

Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer.

Bach PB, Saltz LB.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx125. No abstract available.

PMID:
29059436
40.

FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.

Bach PB, Giralt SA, Saltz LB.

JAMA. 2017 Nov 21;318(19):1861-1862. doi: 10.1001/jama.2017.15218. No abstract available.

PMID:
28975266
41.

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.

Yaeger R, Yao Z, Hyman DM, Hechtman JF, Vakiani E, Zhao H, Su W, Wang L, Joelson A, Cercek A, Baselga J, de Stanchina E, Saltz L, Berger MF, Solit DB, Rosen N.

Cancer Res. 2017 Dec 1;77(23):6513-6523. doi: 10.1158/0008-5472.CAN-17-0768. Epub 2017 Sep 26.

42.

Commentary: Somatostatin analogs-How we choose, and why.

Reidy-Lagunes D, Raj N, Saltz L.

Semin Oncol. 2017 Apr;44(2):157-158. doi: 10.1053/j.seminoncol.2017.08.001. Epub 2017 Aug 4. No abstract available.

PMID:
28923214
43.

OncoKB: A Precision Oncology Knowledge Base.

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.

44.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.

JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137. Erratum in: JAMA. 2018 Dec 11;320(22):2381.

45.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Aug 4;23(8):1004. doi: 10.1038/nm0817-1004c. No abstract available.

PMID:
28777785
46.

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.

Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, Leach T, Herbst B, Askan G, Maynard H, Glassman D, Covington C, Schultz N, Abou-Alfa GK, Harding JJ, Klimstra DS, Hechtman JF, Hyman DM, Allen PJ, Jarnagin WR, Balachandran VP, Varghese AM, Schattner MA, Yu KH, Saltz LB, Solit DB, Iacobuzio-Donahue CA, Leach SD, O'Reilly EM.

Clin Cancer Res. 2017 Oct 15;23(20):6094-6100. doi: 10.1158/1078-0432.CCR-17-0899. Epub 2017 Jul 28.

47.

An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses.

Vasan N, Braghiroli MI, Shoushtari AN, Do RKG, Edelweiss M, Shamseddine A, Faraj W, Mukherji D, Haydar A, Olayan A, Sabatin F, Assi R, El Dika I, Saltz LB, Abou-Alfa GK, O'Reilly EM.

J Gastrointest Oncol. 2017 Jun;8(3):596-602. doi: 10.21037/jgo.2017.01.21. No abstract available.

48.

Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.

Goodman KA, Julie D, Cercek A, Cambridge L, Woo KM, Zhang Z, Wu AJ, Reidy DL, Segal NH, Stadler ZK, Saltz LB.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1087-1095. doi: 10.1016/j.ijrobp.2017.03.022. Epub 2017 Mar 22.

PMID:
28721892
49.

Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

Abou-Alfa GK, Blanc JF, Miles S, Ganten T, Trojan J, Cebon J, Liem AK, Lipton L, Gupta C, Wu B, Bass M, Hollywood E, Ma J, Bradley M, Litten J, Saltz LB.

Oncologist. 2017 Jul;22(7):780-e65. doi: 10.1634/theoncologist.2017-0058. Epub 2017 Jun 7.

50.

How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives.

Zafar SY, Newcomer LN, McCarthy J, Fuld Nasso S, Saltz LB.

Am Soc Clin Oncol Educ Book. 2017;37:35-39. doi: 10.14694/EDBK_174893.

Supplemental Content

Loading ...
Support Center